Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex Vilkin

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
The Israel Medical Association Journal : IMAJ|November 18, 2008
A familial gastrointestinal cancer clinic: organization, aims and activities, 2004-2007Paul Rozen, Zohar Levi, Rachel Hazazi, et al.
Cancer|February 27, 2010
Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical usePaul Rozen, Doron Comaneshter, Zohar Levi, et al.
Harefuah|December 15, 2011
[Management of hereditary non-polyposis syndrome (Lynch syndrome)]Revital Kariv, Yael Goldberg, Irit Soler, et al.
Harefuah|August 31, 2011
[Guidelines for diagnosis, treatment, surveillance and prevention of cancer in patients with familial non-adenomatous polyposis]Elizabeth Half, Yael Goldberg, Revital Kariv, et al.
International Journal of Cancer|July 27, 2010
A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility studyZohar Levi, Shlomo Birkenfeld, Alex Vilkin, et al.
Cancer|January 8, 2009
Microsatellite instability, MLH1 promoter methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in IsraelAlex Vilkin, Yaron Niv, Takeshi Nagasaka, et al.
Annals of Internal Medicine|February 21, 2007
A quantitative immunochemical fecal occult blood test for colorectal neoplasiaZohar Levi, Paul Rozen, Rachel Hazazi, et al.
International Journal of Cancer|June 8, 2019
Association between time to colonoscopy after a positive guaiac fecal test result and risk of colorectal cancer and advanced stage disease at diagnosisAmani Beshara, Maya Ahoroni, Doron Comanester, et al.
Digestive Diseases and Sciences|January 13, 2018
Risk of Neoplastic Progression Among Patients with an Irregular Z Line on Long-Term Follow-UpDavid Itskoviz, Zohar Levi, Doron Boltin, et al.
The American Journal of Gastroenterology|March 19, 2009
Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulantsZohar Levi, Paul Rozen, Rachel Hazazi, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
The Israel Medical Association Journal : IMAJ|November 18, 2008
A familial gastrointestinal cancer clinic: organization, aims and activities, 2004-2007Paul Rozen, Zohar Levi, Rachel Hazazi, et al.
Cancer|February 27, 2010
Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical usePaul Rozen, Doron Comaneshter, Zohar Levi, et al.
Harefuah|December 15, 2011
[Management of hereditary non-polyposis syndrome (Lynch syndrome)]Revital Kariv, Yael Goldberg, Irit Soler, et al.
Harefuah|August 31, 2011
[Guidelines for diagnosis, treatment, surveillance and prevention of cancer in patients with familial non-adenomatous polyposis]Elizabeth Half, Yael Goldberg, Revital Kariv, et al.
International Journal of Cancer|July 27, 2010
A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility studyZohar Levi, Shlomo Birkenfeld, Alex Vilkin, et al.
Cancer|January 8, 2009
Microsatellite instability, MLH1 promoter methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in IsraelAlex Vilkin, Yaron Niv, Takeshi Nagasaka, et al.
Annals of Internal Medicine|February 21, 2007
A quantitative immunochemical fecal occult blood test for colorectal neoplasiaZohar Levi, Paul Rozen, Rachel Hazazi, et al.
International Journal of Cancer|June 8, 2019
Association between time to colonoscopy after a positive guaiac fecal test result and risk of colorectal cancer and advanced stage disease at diagnosisAmani Beshara, Maya Ahoroni, Doron Comanester, et al.
Digestive Diseases and Sciences|January 13, 2018
Risk of Neoplastic Progression Among Patients with an Irregular Z Line on Long-Term Follow-UpDavid Itskoviz, Zohar Levi, Doron Boltin, et al.
The American Journal of Gastroenterology|March 19, 2009
Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulantsZohar Levi, Paul Rozen, Rachel Hazazi, et al.
Pageof 5